Background The association between performance status (PS) and the prognosis of
metastatic renal cell carcinoma (mRCC) patients receiving tyrosine kinase inhibitors (TKIs) …

Objective To compare the effectiveness and safety of treatments for advanced or metastatic
renal cell carcinoma (amRCC) after treatment with vascular endothelial growth factor (VEGF) …

Background: Over the past few years, significant advancements have been achieved in the
front-line treatment of metastatic renal cell carcinomas (mRCCs). However, most patients will …

Simple Summary The management of metastatic renal cell carcinoma (mRCC) represents a
clinical challenge. Progression or toxicity may occur during first-line treatments and many …

Importance Targeted therapies for advanced renal cell carcinoma (RCC) have shown
increased tolerability and survival advantages over older treatments in clinical trials, but …

The large armamentarium of therapies available today for metastatic clear cell renal cell
carcinoma (mCCRCC) has prolonged the survival of these patients in real-life as many of …

Introduction Pivotal Randomized Controlled Trials (RCTs) constitute scientific evidence in
support of therapeutic choices when a drug is authorized in the market. In RCTs, patients are …

BACKGROUND: A key therapeutic goal of metastatic renal cell carcinoma (mRCC) treatment
is delayed disease progression. The degree to which early therapeutic success affects …

Background/aim Sunitinib is used for the treatment of metastatic renal cell carcinoma
(mRCC). Asian patients, including Japanese, tend not to tolerate long-term sunitinib therapy …

In order to facilitate long-term treatment decisions, we aimed to define biomarkers defining
the probability of receiving second-line (SL) targeted therapy (TT) in patients with metastatic …